News

This systematic review and meta-analysis examined how pandemic-related healthcare disruptions led to delays in melanoma diagnoses, resulting in a shift toward more advanced and severe cases. Key findings: ✅ A higher prevalence of poor prognostic factors (thickness, ulceration, mitosis). ✅ A significant increase in advanced-stage melanoma (Stage III & IV). ✅ Highlights the urgent need for updated pandemic preparedness plans to safeguard oncological care. Read […]

This week, the EuCARE team participated in the 23rd European Meeting on HIV & Hepatitis, held in the vibrant city of Barcelona 🇪🇸 We proudly contributed with:🎤 1 oral presentation📌 2 poster presentations This was a fantastic opportunity to share our work, especially on the SCHOOL studies and clinical cohorts, while engaging in meaningful exchanges

Prof. Giulia Marchetti was recently featured in Il Bo Live, the digital magazine of the University of Padua, to discuss the latest insights on Long COVID and its association with other chronic conditions. The interview highlights key findings from the EuCARE POSTCOVID study, as published in BMC Infectious Diseases under the title:“Short and long-term trajectories

EuCARE is heading to Barcelona for the 23rd European Meeting on HIV & Hepatitis (4–6 June) 🇪🇸 Besides being a endorser to the event, we will be presenting: 1 Oral Presentation2 Poster Presentations Our latest findings examine the impact of COVID-19 in school settings — from variant detection to learning loss and mental health concerns.

We’re excited for the ICAR Congress 2025, starting tomorrow in Padua, Italy 🇮🇹 📍 From May 21 to 23, EuCARE will be present with two poster presentations: 🧠 “Trajectories and Predictors of Post-COVID-19 Condition Persistence: A Prospective Evaluation in the EuCARE Study” presented by Dr. Andrea Santoro🎓 “Psychological outcomes and learning loss in students after

EuCARE at the Research to Policy Dialogue on Post COVID-19 Condition We’re proud to share that EuCARE has been selected to present at the upcoming Research to Policy (R2P) Dialogue on Post COVID-19 Condition, organised by the European Commission’s Directorate-General for Research and Innovation (DG R&I) in collaboration with the European Centre for Disease Prevention and

We’re excited to share the video wrap-up of the joint EuCARE & VIROMARKERS session at the AREVIR Meeting 2025. This special session brought together leading scientists to discuss research synergies, share preliminary results, and explore future challenges in infectious diseases and virology. A big thank you to all who joined us in Cologne or followed

Today, on May 9th, we celebrate #EuropeDay2025, marking 75 years of unity and cooperation across Europe 🇪🇺 Meanwhile, our EuCARE team is gathered in Cologne 🇩🇪 for the joint EuCARE & VIROMARKERS session at the AREVIR Meeting 2025 — sharing knowledge and building the future of infectious disease research together. We are proud to be

We’re pleased to share the final outputs of the COVID Cohorts Policy Insight Series, developed between March 2024 and March 2025 under the leadership of CoVICIS. These resources synthesize key policy insights from EU-funded COVID cohort consortia — including EuCARE — and are now available in modular format, as well as a full technical report:🗂️

We are proud to announce that the abstract “Trajectories and Predictors of Post-COVID-19 Condition Persistence: A Prospective Evaluation in the EuCARE Study” has been accepted as a poster presentation at the ICAR Congress 2025, taking place in Padua, Italy, from May 21–23. A big thank you to Dr. Andrea Santoro and all collaborators involved in